The patient support program Cycle Vita will be available for people with MS taking Bafiertam (monomethyl fumarate) starting ...

Tom Nolan reviews this week’s research There are so many studies published about vitamin D—about a dozen each day—it’s hard to keep up. One that stands out is a double-blind randomised controlled ...

A new health care plan for Alabama’s farmers is on the table, promising to be the most comprehensive and restrictive of its ...

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability ...

A woman whose 'strange episodes' as a teen were diagnosed as anxiety after she woke up sick with a sense of deja vu was told ...

A local naval officer is fearlessly facing his multiple sclerosis diagnosis, using his creativity and entrepreneurial skills ...

(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...

Salma Said had never heard of multiple sclerosis (MS) when she experienced her first attack on her 20th birthday on April 30, ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Columnist Desiree Lama remembers how a best friend helped her with stressful assignments and RRMS symptoms in college.

A new study suggests that high doses of vitamin D supplements could help reduce disease activity among multiple sclerosis ...